Yves Champey Takes Over From Bernard Barataud
EVRY, France, July 7 /CNW/ - The board of directors at Genethon nominated
a new president to head the laboratory created in 1990 by the AFM (French
Muscular Dystrophy Association). Thus Yves Champey succeeds Bernard Barataud,
who has decided to hand over the reins after heading the laboratory between
1990 and 1995 and then between 1999 and 2008.
Yves Champey is a physician by training. Genethon will benefit from his
international experience with responsibility for the development of new drugs
within major pharmaceutical companies such as Pfizer and Rhone-Poulenc Rorer.
Also, he contributed to the creation of the Drug for Neglected Diseases
Initiative (DNDi) - of which he was president from 2003 to 2007. The DNDi is a
foundation dedicated to the research and development of new drugs against
neglected parasite diseases affecting poor populations. Finally, with Pierre
Tambourin, he has been deeply involved in the development of Genopole(R) Evry,
and is president of the board of directors of the pre-seed fund G1J
"I will be placing all my experience at the service of the AFM and
Genethon," declares Yves Champey, "with 3 objectives: successfully
implementing the clinical trials programs, reinforcing the position of
Genethon as a not-for-profit entity of research and development, and
developing the innovative biotherapies for the treatment of rare diseases. My
ambition is also to open the way to substantial joint projects with the
pharmaceutical and biotechnological industries and to develop those that
already exist with public research organisations."
President of the AFM (French Muscular Dystrophy Association) from 1981 to
2001, Bernard Barataud is the father of three children, one of whom died from
Duchenne myopathy in 1986 at the age of sixteen. Co-founder of the French
Telethon in 1987, he was also the founder of Genethon in 1990 with the Nobel
Prize winner Jean Dausset. As early as 1992 Genethon supplied the
international scientific community with the first maps of the human genome.
This considerably accelerated its deciphering and the discovery of the genes
responsible for diseases. It is this progress which has led to innovative
therapies based on knowledge of genes, therapies which are now undergoing
clinical trials. Eighteen years after its creation, Genethon is today a
not-for-profit biotechnology enterprise whose aim is to develop biotherapies
for rare genetic diseases. Genethon is the promoter of the first gene therapy
trial in humans for gamma-sarcoglycan deficiency. It possesses two clinical
batch production units for vectors and is engaged in the development of a
pre-industrial scale BMP production site to go onstream in 2010.
For further information:
For further information: Estelle Rozine Assaf - +33-1-69-47-28-28,